Drugs /

lisavanbulin

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of BAL101553 and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.

Clinical Trials

View Clinical Trials for lisavanbulin

Lisavanbulin has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating lisavanbulin, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for lisavanbulin clinical trials.

Adenocarcinoma of the gastroesophageal junction, breast carcinoma, and colorectal carcinoma are the most common diseases being investigated in lisavanbulin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lisavanbulin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lisavanbulin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lisavanbulin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bal101553, microtubule-targeted agent bal101553, microtubule-targeted agent bal101553, bal-101553
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C97664

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.